---
title: "Quarto Cheat Sheet"
subtitle: "Subtitle"
author: "Jonathan C Salo MD"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    #css: ["theme/theme.css"]
    theme: default
      
    echo: false
editor: visual
bibliography: zotero.bib
---

## Tables

| Category             |   Stage    | Treatment                  |
|----------------------|:----------:|:---------------------------|
| [Dyplasia]           |    Tis     | Radiofrequency Ablation    |
| [Superficial Tumors] |    T1a     | Endoscopic Therapy         |
| [Localized Tumors]   |   T1b T2   | Surgery                    |
| [Locally-advanced]   | T3 or N^+^ | ChemoRT â†’ Surgery          |
| [Metastatic]         |     M1     | Chemotherapy +/- Radiation |

## Symbols


$\alpha$
$\rightarrow$
$\leftarrow$
$\longrightarrow$
$\implies$
$\gt$
$\pi r^2$
$\leq$
$\geq$
$\beta_1$
$\tilde{x}$
$\checkmark$
$\bullet$
$\dagger$
$\downarrow$
$\ll$
$\gg$
$\pm$
$\div$
$\star$
$\nearrow$
$\searrow$
$\leadsto$
$\surd$
$\therefore$
$\neq$
$\notin$
$\tilde{x}$

Inline fractions

$\frac{SMI\, \times \,SMD}{\mathrm{Height\, in\, meters}^2}$

Offsest math with double-dollar signs

$$\frac{SMI\, \times \,SMD}{\mathrm{Height\, in\, meters}^2}$$

## Table with flextable

```{r}
#| label: tbl-xyz-flextable
#| tbl-cap: Table of x, y, z (made with the flextable package)

xyz<-data.frame(matrix(rnorm(8),nrow=4))

#library(flextable)
#flextable(xyz)
```

## Table with Kable

```{r}
#| label: tbl-LABEL
#| tbl-cap: CAPTION

knitr::kable(head(cars))
```

## Hyperlinks

[syllabus](https://www.albany.edu/spatial/GIS4SS/syllabus/){target='_blank'}



## Columns

Radiofrequency Ablation for Dysplasia

::: columns
::: {.column width="60%"}
127 patients with dysplasia randomized:

-   Radio-frequency ablation
-   Sham ablation

Low-grade dysplasia in 64

High-grade dysplasia in 63
:::

::: {.column width="40%"}
![](images/rfa_esophagus.png) ![Barxx](images/barxx.png)
:::
:::

::: aside
[@shaheen2277]
:::

## Radiofrequency Ablation for Dysplasia

::: columns
::: {.column width="30%"}
Radiofrequency Ablation results in eradication of Barrett's in 75% at 1 year
:::

::: {.column width="70%"}
![](images/shaheen.png)
:::
:::

::: aside
[@shaheen2277]
:::


## Full-page images

![](images/EMR.jpg){fig-align="right"}

## Symptomatic Tumors (Dysphagia)

Patients with dysphagia to solids or weight loss or tumor length \>3cm are unlikely to have T1-2 tumors and can be initially evaluated with [PET Scan]

-   Disease confined to the esophagus and regional nodes $\rightarrow$ [Locally-advanced]
-   Metastatic disease $\rightarrow$ [Metastatic]
-   N3 $\rightarrow$ induction chemotherapy followed by chemoradiation and surgical evaluation.

## EUS in Patients with Dysphagia

Memorial Sloan Kettering[^1] patients with esophageal cancer:

[^1]: @ripley226

-   61 with dysphagia, 54 (89%) were found on EUS to have uT3-4 tumors.
-   53 without dysphagia, 25 (47%) were uT1-2 $\rightarrow$ candidates for primary surgery.

EUS can be omitted for patients with dysphagia, but is useful in patients *without* dysphagia.

## PET Scan

PET has more specificity and sensitivity than CT in detecting regional lymph node and distal metastasis [^2]

[^2]: @block770


## CROSS Trial

-   368 esophageal cancer patients randomized:
    -   Surgery alone
    -   Chemo+RT $\rightarrow$ Surgery
-   75% adenocarcinoma
-   T3: 80%. T2: 17%
-   age $\tilde{x}$=60
-   longer survival with Chemo+RT $\rightarrow$ Surgery

CROSS Trial Details

Chemotherapy: Weekly carboplatin and paclitaxel 
Radiation: 4140 cGy in 23 fractions (180cGy/fraction)

::: aside
[@shapiro1090]
:::

## CROSS - Overall Survival

![Surgery vs ChemoRT $\rightarrow$ Surgery](images/shapiro_1090_fig2a.png){fig-align="left"}

::: aside
[@shapiro1090]
:::


## CROSS - Squamous cell carcinoma

Median survival 82mo vs 21mo

Pathologic complete respoinse in 40%

::: aside
[@shapiro1090]
:::

## CROSS - Sites of Failure

::: columns
::: {.column width="30%"}
Sites of failure over time

ChemoRT + Surgery *vs* Surgery

ChemoRT appears to reduce risk of local or local+distant failure, but not isolated distant failure
:::

::: {.column width="70%"}
![](images/eyck.png)
:::
:::

::: aside
[@shapiro1090]
:::

## Neoadjuvant Chemo for EsoCA

-   MAGIC trial (gastric): ECF[^3]$\rightarrow$Surgery$\rightarrow$ECF *vs* Surgery\
-   OEO2 Trial: (esophageal) Chemo$\rightarrow$Surgery$\rightarrow$ Chemo *vs* Surgery\
-   FLOT (gastric): FLOT[^4]$\rightarrow$Surgery$\rightarrow$ FLOT *vs* ECF$\rightarrow$Surgery$\rightarrow$ECF
-   EsoPEC: (esophageal):FLOT$\rightarrow$Surgery$\rightarrow$FLOT *vs* ChemoRT$\rightarrow$Surgery (CROSS)

[^3]: Epirubicin, Cisplatin, 5FU

[^4]: 5FU, Leuvocorin, Oxaliplatin, Decetaxol


## Include Other Slideshows

{{< include rectal_slides.qmd >}}

## Orientation Manual

{{< qrcode https://gisurgonc.github.io/orientation width=500 height=500 >}}

## References

:::{#refs}
:::
